Kaya (OTCMKTS:KAYS – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Institutional and Insider Ownership
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 23.5% of Kaya shares are owned by company insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations for Kaya and Aurinia Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kaya | 0 | 0 | 0 | 0 | 0.00 |
| Aurinia Pharmaceuticals | 0 | 1 | 3 | 0 | 2.75 |
Risk and Volatility
Kaya has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Profitability
This table compares Kaya and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kaya | N/A | -9.79% | -1,143.19% |
| Aurinia Pharmaceuticals | -10.23% | -4.41% | -3.07% |
Valuation and Earnings
This table compares Kaya and Aurinia Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kaya | $200,000.00 | 4.29 | $1.61 million | ($0.08) | -0.48 |
| Aurinia Pharmaceuticals | $175.51 million | 6.53 | -$78.02 million | ($0.15) | -53.33 |
Kaya has higher earnings, but lower revenue than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Kaya, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Kaya on 9 of the 14 factors compared between the two stocks.
About Kaya
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Kaya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaya and related companies with MarketBeat.com's FREE daily email newsletter.
